CDEK
← All drugs Report issue

alisertib

Small moleculeexperimental

Alisertib (MLN8237) is an orally available, investigational, reversible, ATP-competitive, selective aurora A kinase inhibitor developed by Takeda. Inhibition of aurora A kinase A leads to disruption of mitotic spindle apparatus assembly, disruption of chromosome segregation, and inhibition of cell proliferation. — Wikipedia

Clinical trial activity

63 trials · 31 clinical orgs · 0 marketing orgs

Phase 1
41
Phase 2
27
Phase 3
1
Phase 4
0

Earliest trial started May 1, 2007 (NCT00500903)

Timeline

2000s

  1. Jan 1, 2007

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2009

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2012

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O
Mol. weight
518.93 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • alisertib
  • alisertib
  • alisertib
  • alisertib
  • alisertib
  • alsertib
  • mln8237
  • mln8237
  • mln8237
  • mln 8237
  • mln-8237
  • mln-8237
  • mln-8237

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06369285Phase 2Dec 31, 2024Puma Biotechnology, Inc.
NCT06095505Phase 2Dec 31, 2023Puma Biotechnology, Inc.
NCT04555837Phase 1/Phase 2 (Phase 2)Sep 15, 2020National Cancer Institute (NCI), University of Texas at Houston
NCT04479306Phase 1Jun 18, 2020University of Texas at Houston
NCT04085315Phase 1Aug 23, 2019Takeda, University of California, San Francisco
NCT02860000Phase 2Jul 28, 2017Mayo Clinic, National Cancer Institute (NCI)
NCT03005262N/ADec 22, 2016University of Texas, San Antonio
NCT02700022Phase 1Oct 1, 2016Millennium Pharmaceuticals, University of North Carolina at Chapel Hill
NCT02780011Phase 1Sep 1, 2016Methodist Cancer Center, Houston, Texas, Millennium Pharmaceuticals
NCT02812056Phase 1Sep 1, 2016Millennium Pharmaceuticals, University of Texas at Houston
NCT02719691Phase 1May 13, 2016University of Colorado, Denver
NCT02560025Phase 2Dec 1, 2015Harvard University, Takeda
NCT02530619N/AOct 1, 2015Millennium Pharmaceuticals, National Cancer Institute (NCI), Northwestern University, The Leukemia and Lymphoma Society
NCT02551055Phase 1Sep 1, 2015Millennium Pharmaceuticals, Takeda
NCT02319018Phase 1Aug 27, 2015National Cancer Institute (NCI), Yale University
NCT02293005Phase 2May 20, 2015Millennium Pharmaceuticals, University of Texas at Houston
NCT02367352Phase 1Mar 25, 2015Millennium Pharmaceuticals
NCT02327169Phase 1Feb 2, 2015Millennium Pharmaceuticals, Takeda
NCT02187991Phase 2Feb 1, 2015Millennium Pharmaceuticals, US Oncology
NCT02186509Phase 1Jan 1, 2015Millennium Pharmaceuticals, Thomas Jefferson University
Showing 20 of 63 trials
Page 1 / 4

Organizations

Research & Development (31)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Millennium PharmaceuticalsFor profit362342007
National Cancer Institute (NCI)Government161032008
TakedaFor profit6022013
University of Texas at HoustonAcademic/Hospital5422013
Harvard UniversityAcademic/Hospital3222012
Mayo ClinicAcademic/Hospital3322010
Puma Biotechnology, Inc.For profit2212023
Thomas Jefferson UniversityAcademic/Hospital2222013
University of California, DavisAcademic/Hospital2212013
City of Hope National Medical CenterAcademic/Hospital1012012
Cornell UniversityAcademic/Hospital1112013
Emory UniversityAcademic/Hospital1112013
Methodist Cancer Center, Houston, TexasAcademic/Hospital1112016
Northwestern UniversityAcademic/Hospital1112015
NRG OncologyAcademic/Hospital1012012
Ohio State UniversityAcademic/Hospital1012013
Southwest Oncology GroupAcademic/Hospital1012011
St. Jude Children's HospitalAcademic/Hospital1112014
Temple UniversityAcademic/Hospital1112011
The Leukemia and Lymphoma SocietyAcademic/Hospital1012015
31 organizations
Page 1 / 2